norepinephrine

all catalysts(1)

News(9)

• Caribou to stop R&D work, start ‘substantial’ job cuts
  Follow along as BioSpace tracks job cuts and restructuring initiatives.
  biospace · 9h ago
• Biotech’s peptide shows promise as ‘bait molecule’ to treat neuropathic pain in mice
  While psychedelic drugs may be capturing all the attention when it comes to finding fresh ways to treat neuropathic pain, research with mice has suggested a peptide approach may also be effective.
  fiercebiotech · 3d ago
• Psilocybin proves promising in neuropathic pain mouse study
  Amid the rise of psychedelics in the mental health space, researchers have begun to explore psilocybin as a treatment for chemotherapy-induced peripheral neuropathy.
  fiercebiotech · 1mo ago
• ‘A neuroscience revolution’: The GLP-like race to keep us awake and make billions doing it
  As the hype around the vast medical potential of GLP-1 drugs continues unabated, another peptide is starting to make its own mark.
  fiercebiotech · 1mo ago
• Takeda leads wave of orexin drugs with potential to upend narcolepsy market
  The FDA’s August approval of Takeda’s Orzeyful for treating the full set of narcolepsy symptoms initiated a new era in the sleep market.
  biospace · 1mo ago
• Psychedelics on the cusp of market breakthrough as clinical, policy support grow
  While there are several FDA-approved psychiatric medicines on the market, many patients still struggle to achieve lasting symptom relief. Psychedelics could help fill this gap.
  biospace · 1mo ago
• FDA scientists question Capricor data; Legend CEO steps down
  Capricor shares lost much of their value ahead of a high-stakes advisory committee meeting. Elsewhere, Ying Huang’s resignation extended a stock slide for Legend and AstraZeneca disclosed more pipe…
  biopharma_dive · 2mo ago
• Otsuka’s ADHD approval opens up new drug class with $615M opportunity
  Otsuka Pharmaceutical plans to launch Simtriyo—the first norepinephrine, dopamine, serotonin reuptake inhibitor—later this year following scheduling by the U.S. Drug Enforcement Agency.
  biospace · 2mo ago
• FDA accepts Replimune filing; Merck KGaA drops $11B on life sciences services
  Replimune’s application is the latest example of changing attitudes at the FDA. Elsewhere, Revolution Medicines outlined more RAS-blocking data and a Definium stock offering brought in $800 million.
  biopharma_dive · 3mo ago